BRPI0922681A2 - nucleiotídeos de uracil ciclopropila - Google Patents

nucleiotídeos de uracil ciclopropila

Info

Publication number
BRPI0922681A2
BRPI0922681A2 BRPI0922681A BRPI0922681A BRPI0922681A2 BR PI0922681 A2 BRPI0922681 A2 BR PI0922681A2 BR PI0922681 A BRPI0922681 A BR PI0922681A BR PI0922681 A BRPI0922681 A BR PI0922681A BR PI0922681 A2 BRPI0922681 A2 BR PI0922681A2
Authority
BR
Brazil
Prior art keywords
uracil
cyclopropyl
nucleotides
uracil cyclopropyl
cyclopropyl nucleotides
Prior art date
Application number
BRPI0922681A
Other languages
English (en)
Inventor
Koen Vandyck
Leen Anna Maria Vandekerckhove
Pierre Jean-Marie Bernard Raboisson
Steven Maurice Paula Van Hoof
Tim Hugo Maria Jonckers
Original Assignee
Centocor Ortho Biotech Products L P
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Products L P, Medivir Ab filed Critical Centocor Ortho Biotech Products L P
Publication of BRPI0922681A2 publication Critical patent/BRPI0922681A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0922681A 2008-12-08 2009-12-08 nucleiotídeos de uracil ciclopropila BRPI0922681A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08171006 2008-12-08
PCT/EP2009/066562 WO2010066699A1 (en) 2008-12-08 2009-12-08 Uracyl cyclopropyl nucleotides

Publications (1)

Publication Number Publication Date
BRPI0922681A2 true BRPI0922681A2 (pt) 2016-01-05

Family

ID=40852521

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922681A BRPI0922681A2 (pt) 2008-12-08 2009-12-08 nucleiotídeos de uracil ciclopropila

Country Status (21)

Country Link
US (1) US8399429B2 (pt)
EP (1) EP2373671B1 (pt)
JP (1) JP5683480B2 (pt)
KR (1) KR20110104000A (pt)
CN (1) CN102256991B (pt)
AP (1) AP2011005717A0 (pt)
AR (1) AR074504A1 (pt)
AU (1) AU2009326125B2 (pt)
BR (1) BRPI0922681A2 (pt)
CA (1) CA2745523C (pt)
CL (1) CL2011001364A1 (pt)
EA (1) EA020244B1 (pt)
ES (1) ES2525007T3 (pt)
IL (1) IL212897A (pt)
MX (1) MX2011006023A (pt)
PA (1) PA8852101A1 (pt)
SG (1) SG171973A1 (pt)
TW (1) TW201036989A (pt)
UY (1) UY32308A (pt)
WO (1) WO2010066699A1 (pt)
ZA (1) ZA201104231B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3027B1 (ar) * 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
WO2013174962A1 (en) 2012-05-25 2013-11-28 Janssen R&D Ireland Uracyl spirooxetane nucleosides
ES2725491T3 (es) * 2012-11-16 2019-09-24 Univ College Cardiff Consultants Ltd Mezcla de RP/SP gemcitabina-[fenil-(benciloxi-L-alaninil)]-fosfato
KR101857337B1 (ko) * 2013-03-08 2018-05-11 난징 산홈 팔마세우티칼 컴퍼니 리미티드 신규한 뉴클레오시드 포스포라미데이트 화합물 및 이의 용도
CN103848876B (zh) * 2013-03-25 2016-05-11 安徽贝克联合制药有限公司 一种核苷磷酰胺前药及其制备方法和其应用
WO2014169278A1 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of hcv
CN105348342B (zh) * 2014-09-30 2018-09-21 南京正大天晴制药有限公司 核苷氨基磷酸酯化合物及药物组合物和用途
WO2016073756A1 (en) * 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
CN105801646B (zh) * 2014-12-31 2019-08-16 浙江大德药业集团有限公司 炔基取代的核苷氨基磷酸酯
WO2016134053A1 (en) * 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
GEAP202215528A (en) 2015-03-06 2022-11-10 Atea Pharmaceuticals Inc B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
EP3344642A1 (en) 2015-09-02 2018-07-11 AbbVie Inc. Anti-viral tetrahydrofurane derivatives
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
BR112019004297A2 (pt) 2016-09-07 2019-05-28 Atea Pharmaceuticals Inc método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica.
SG11201906163TA (en) 2017-02-01 2019-08-27 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
KR100187990B1 (ko) 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 레트로바이러스성 프로테아제 억제 화합물 제조용 합성 중간체
US20010021509A1 (en) * 1997-10-23 2001-09-13 Sathe Ganesh Madhusudan cDNA clone HNEAA81 that encodes a human 7-transmembrane receptor
TW200500375A (en) * 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
CA2514466C (en) * 2003-02-19 2015-05-26 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections
CA2523083C (en) * 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US8802840B2 (en) * 2005-03-08 2014-08-12 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
HRP20110193T1 (hr) 2006-10-10 2011-05-31 Medivir Ab Inhibitor hcv nukleozida

Also Published As

Publication number Publication date
CL2011001364A1 (es) 2011-09-23
JP5683480B2 (ja) 2015-03-11
EP2373671A1 (en) 2011-10-12
ZA201104231B (en) 2012-11-28
EP2373671B1 (en) 2014-09-10
PA8852101A1 (es) 2010-07-27
CA2745523C (en) 2017-07-04
CN102256991A (zh) 2011-11-23
KR20110104000A (ko) 2011-09-21
WO2010066699A1 (en) 2010-06-17
UY32308A (es) 2010-06-30
US8399429B2 (en) 2013-03-19
IL212897A (en) 2013-12-31
MX2011006023A (es) 2011-06-28
ES2525007T3 (es) 2014-12-17
AU2009326125B2 (en) 2015-03-12
EA201170780A1 (ru) 2011-12-30
TW201036989A (en) 2010-10-16
AU2009326125A1 (en) 2010-06-17
AR074504A1 (es) 2011-01-19
CN102256991B (zh) 2015-08-12
SG171973A1 (en) 2011-07-28
IL212897A0 (en) 2011-07-31
CA2745523A1 (en) 2010-06-17
JP2012510980A (ja) 2012-05-17
AP2011005717A0 (en) 2011-06-30
EA020244B1 (ru) 2014-09-30
US20110230436A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
BRPI0922681A2 (pt) nucleiotídeos de uracil ciclopropila
HRP20181774T1 (hr) Novi citostatski 7-deazapurinski nukleosidi
BRPI1010579A2 (pt) espiro-oxetano nucleosídeos de uracila.
SMT201600351B (it) Composti antivirali
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
ZA201008829B (en) Nucleoside cyclicphosphates
BRPI0922508A2 (pt) Análogos de nucleosídeo
BRPI0913643A2 (pt) inibidores de ciclopropil polimerase
AP2011005929A0 (en) Substituted nucleoside and nucleotide analogs.
BRPI0914544A2 (pt) derivados de pirimidona substituídos
EP2794627A4 (en) SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUE THEREOF
BRPI0819797A2 (pt) compostos de nucleosídeos antivirais
BRPI0907885A2 (pt) Compostos antiviras hetrocíclicos
DK2154967T3 (da) Pyrimidinderivater
EP2414109A4 (en) Metallic ink
BRPI0911695A2 (pt) conjunto de barbear
BRPI0817444A2 (pt) Prímeres de poliunucleotídeo
BRPI0920496A2 (pt) derivados substituídos de pirimidina etriazina
BRPI1013493A2 (pt) composto de pirimidina
BRPI0811115A2 (pt) Compostos de heteroarilamida pirimidona
BRPI0910534A2 (pt) terapia antiviral
BRPI0916679A2 (pt) 5-alquinil-pirimidinas
BRPI0914936A2 (pt) naftiridininonas como inibidores de aurora quinase
BRPI0917673A2 (pt) Combinação de herbicida-protetor compreendendo difluorometanossulfonilanilidas substituidas por dimetoxitriazinila
FR2959228B1 (fr) Nucleotides modifies

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]